ArticleJapanese journal of clinical oncology2025
Safety and effectiveness of tepotinib in patients with unresectable, advanced or recurrent non-small cell lung cancer with METex14 skipping alterations: post-marketing surveillance in Japan.
Article in Japanese journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Management of Adverse Events Associated with MET TKIs in Patients with Advanced NSCLC: A Podcast Discussion.Targeted oncology · 2026Article
- Targeted Therapy-Induced Interstitial Lung Disease in NSCLC: Mechanisms, Clinical Signatures, and a Precision Medicine Roadmap.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTepotinib has shown clinical benefits in patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping alterations. The objective of this post-marketing surveillance (PMS) was to assess the safety and effectiveness of tepotinib in general clinical practice in Japan.
methodsThis multicenter, non-interventional PMS included patients with unresectable, advanced, or recurrent NSCLC with METex14 skipping alterations who received at least one dose of tepotinib. The primary endpoint was the incidence of adverse drug reactions (ADRs) identified as safety specifications (SS) for tepotinib according to the Japanese Risk Management Plan (ADRs of SS); i.e. interstitial lung disease (ILD), fluid retention, hepatic function disorder, renal impairment, and QT interval prolongation (classified by preferred term). The secondary endpoints were ADRs of SS in patient subgroups and the effectiveness of tepotinib in clinical practice. In total, 147 patients were included (median age 72.0 years).
resultsThe incidence of ILD, fluid retention, hepatic function disorder, and renal impairment was 7.5%, 47.6%, 13.6%, and 36.1%, respectively; incidence of grade ≥3 ADRs of SS were 3.4%, 9.5%, 4.8%, and 2.7%, respectively. No instances of QT interval prolongation occurred. Four patients (2.7%) died due to ILD. The objective response rate was 51.0% [95% confidence interval (CI) 42.7, 59.3] and disease control rate was 77.6% (95% CI 69.9, 84.0).
conclusionsTepotinib was generally well tolerated and effective in patients with NSCLC and METex14 skipping alterations in general clinical practice in Japan; no new safety issues or concerns were identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.